Crossmark

Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain

Crossref DOI link: https://doi.org/10.1186/s13561-017-0181-3

Published Online: 2017-12-19

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schmidt, Ralph https://orcid.org/0000-0002-5045-0005
Majer, Istvan

García Román, Natalia

Rivas Basterra, Alejandra

Grubb, ElizaBeth

Medrano López, Constancio
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2017-12-01
More Information

Article History

Received: 2 May 2017

Accepted: 13 November 2017

First Online: 19 December 2017

Competing interest

: Employees of Pharmerit International were paid consultants to AbbVie for performing the described research and have no conflict of interest to report. NGR, ARB and EG are employees of AbbVie and may hold AbbVie stock. The authors attest that any and all financial or other relationships, including financial support of the study that could be construed as a conflict of interest have been disclosed here. All authors have read and approved the final draft of the manuscript.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below